Thu
Jun
20, 2024
Los Angeles : 09:00 AM - 10:00 AM
NEW YORK:
Jun 20 • 12:00 PM - 01:00 PM
LONDON:
Jun 20 • 05:00 PM - 06:00 PM
PARIS:
Jun 20 • 06:00 PM - 07:00 PM
INDIA:
Jun 20 • 09:30 PM - 10:30 PM
CHINA:
Jun 21 • 12:00 AM - 01:00 AM
SYDNEY:
Jun 21 • 02:00 AM - 03:00 AM
Seminar
Co-organized with
There is no cost to register for this activity.
Moderator(s):
Mari DeMarco, PhD, DABCC, FACB, FCACB University of British Columbia
Can pre-clinical proteomics support therapy selection in precision medicine? A proof of
concept.
Philipp Lange, PhD
BC Children's Hospital, University of British Columbia
Dr. Philipp Lange is Canada Research Chair in Translational Proteogenomics of Pediatric Malignancies and Associate Professor of Pathology at the University of British Columbia (UBC). He is also a Scientist in the Michael Cuccione Childhood Cancer Research Program at the BC Children’s Hospital and the BC Cancer Research Institute.
Dr. Lange’s research focuses on precision oncology and oncoproteoforms, proteins with cancer-specific post-translational modification, their altered function, role in cell-cell communication and drug resistance, and their potential use as drug targets and biomarkers. His team drives the development and translation of proteomics platforms to advance molecular pathology and guide precision treatment for kids with cancer.
Dr. Lange provides leadership for Cancer Biology in the Canadian Pediatric Cancer Consortium ACCESS and co-leads the multi-centre proteomics team in the Canadian Precision Oncology For Young People (PROFYLE) study. He has won several awards for his advances in cancer research including the CIHR Early Career Investigator in Cancer Award and the Great Canadian Innovation Award by the Canadian Cancer Society.
Dr. Philipp Lange received his PhD in Biochemistry from the Free University Berlin, Germany after earning an MSc in Molecular Biology, Microbiology and Computer Sciences from the University of Hamburg, Germany. During his PhD with Dr. Dr. Thomas Jentsch at the Max Delbruck Centre for Molecular Medicine, Berlin, Germany he studied the molecular causes of hereditary osteopetrosis in children and patented a new drug target for the treatment of osteoporosis in adults. He conducted his postdoctoral work with Dr. Christopher Overall at the Centre for Blood Research, UBC developing computational and proteomics approaches to study post-translational modification in cancer.
Molecularly targeted precision treatments have significant potential to improve therapy options for hard-to-treat cancers and reduce late effects in general. Genome sequencing has laid the foundation for precision medicine, yet, clinical success remains moderate. Identifying therapeutic targets at the protein and pathway level by mass spectrometry-based proteomics holds great promise.
I will discuss analytical and systems challenges and propose possible strategies to smooth the path to full clinical translation. I will then present a proof of principle study in which we identified a possible treatment target in an adolescent with a recurrent rare malignancy. Within two weeks from biopsy, we conducted comprehensive DIA proteomics on H&E stained FFPE sections and validated a putative target by IHC. Following additional validation and failed chemotherapy and second line treatment the patient initiated a proteome guided monotherapy trial. I will then present an outlook how we envision to make pre-clinical proteome analysis and other innovative molecular pathology tests available to all children with cancer across Canada.
Co-organized with the Canadian National Proteomics Network.
Info on CNPN 2024.